Efalizumab (Raptiva) for treatment of psoriasis.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D005334:Fever / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008297:Male; D011000:Pleurodynia, Epidemic / Q000139:chemically induced; D011565:Psoriasis / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C472181:efalizumab